Therefore, after the discovery of the crosstalk and relation between LKB1 and SRC/FAK and their important role in cell mobility, this pathway became an interesting potential target for LKB1-mutated NSCLC therapies. Here, PTK2 is linked to non-small cell lung carcinoma.